Notably, we showcased the DM target genes, namely, JAK1, JAK2, IFNAR1, IFNAR2 CD4, and FCGR3B, corresponding to nine drug-target combinations that could potentially be repositioned for DM. This evidence concerns the gene FCGR3B and dermatomyositis.